- Home
- MRK
as 07-07-2025 4:00pm EST
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | RAHWAY |
| Market Cap: | 198.5B | IPO Year: | N/A |
| Target Price: | $113.71 | AVG Volume (30 days): | 17.8M |
| Analyst Decision: | Buy | Number of Analysts: | 15 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 6.88 | EPS Growth: | 667.14 |
| 52 Week Low/High: | $73.31 - $129.93 | Next Earning Date: | 07-29-2025 |
| Revenue: | $63,922,000,000 | Revenue Growth: | 4.10% |
| Revenue Growth (this year): | 2.42% | Revenue Growth (next year): | 5.77% |
Latest Merck & Company Inc. (new) News
MRK Breaking Stock News: Dive into MRK Ticker-Specific Updates for Smart Investing
Zacks
21 hours ago
SMMT Stock Gains on Rumored Licensing Talks With AstraZeneca
CNW Group
21 hours ago
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
GlobeNewswire
a day ago
mRNA Cancer Vaccines Clinical Trials & Future Market Outlook 2025: Personalized mRNA Cancer Vaccines Revolutionize Oncology with Neoantigen-Driven Immunotherapy
Insider Monkey
2 days ago
FDA Grants Priority Review for Merck & Co’s (MRK) WINREVAIR
Insider Monkey
2 days ago
Merck & Co (MRK) Announces the Approval of ENFLONSIA
Simply Wall St.
4 days ago
Top Dividend Stocks To Consider In July 2025
Zacks
4 days ago
Will Novo Nordisk's Rare Disease Bets Reduce GLP-1 Reliance?
GlobeNewswire
4 days ago
Sodium Perborate Market worth $184.0 million in 2030, at 3.7%, says MarketsandMarkets™
Compare MRK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MRK Merck & Company Inc. (new) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.